Conferences & Events

Combination therapy for cancer: using immunotherapy and viruses webinar

April 18, 2024 (1:00 PM-2:00 PM Eastern Time)

While immunotherapy activates the immune system against cancer cells, its efficacy varies among patients. Oncolytic viruses selectively infect cancer cells and induce immunogenic cell death, making them an appealing adjunctive approach to enhance therapeutic responses. However, translating research findings into clinical success has been challenging. In this webinar, Howard Kaufman will discuss the current treatment landscape, challenges, and promising strategies for using oncolytic viruses in combination therapy for cancer. 

Topics to be covered

• Clinical and logistical challenges of using oncolytic viruses
• New strategies for combining oncolytic viruses and cancer immunotherapy

Development of a Cell-Based Reporter Assay for Measuring ADAR1 Editing Activity for Drug Discovery and Cell Biology Research

May 21, 2024 (8:00 AM PT, 11 AM ET)

Adenosine Deaminase Acting on RNA (ADAR) enzymes perform adenosine to inosine base editing in RNA, particularly targeting adenosines located within a specific double-stranded stem-loop motif.  ADAR1 plays important roles in inflammation, autoimmune diseases, and cancer, and represents an attractive target for therapeutic development.

BPS Bioscience has developed and validated high-throughput, cell-based assays for measuring ADAR1 editing activity.  This webinar will describe the principle of these cell-based assays, present data, and discuss the scientific applications of the cell lines.

You will learn about:

• The function of ADAR1
• How ADAR1 RNA-editing activity can be measured using a luciferase reporter system
• The research applications of ADAR1 reporter cell-based assays